About this trial
The hypothesis of the study is that non-invasive Single photon emission computed tomography (SPECT-CT) bone scintigraphy makes it possible to better characterize solitary bone lesions, in particular the exclusion of their malignancy in order to avoid unnecessary biopsy and possible complications for the patient.
Eligibility criteria
Qualifiers
Age ≥ 18 years old.
Having read and understood the information document.
Affiliated to a social security scheme.
Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy +/- excision is planned.
Disqualifiers
Pregnant woman or woman of childbearing age and without contraceptive means or nursing mother.
Unstable medical condition and/or inability to remain still during recordings.
Known allergy to one of the components of the radiopharmaceutical technetium-99m-Technescan HDP (product required to perform the bone scan).
Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.
Trial design
Treatments tested in this trial
- Bone scan